California-based startup Genesis Therapeutics has successfully raised $200 million in a Series B funding round, with the funds earmarked for advancing the clinical trials of its AI-driven drug projects and expanding research into new areas. This round of financing was co-led by Andreessen Horowitz and an undisclosed life sciences investor. Genesis Therapeutics focuses on utilizing artificial intelligence to model and predict the properties of proteins and their molecular partners, having secured over $280 million in cumulative funding to date. The company's work has attracted the attention of pharmaceutical giants Eli Lilly and Roche, with whom they are collaborating on drug development.